news
Empty Hepatitis E virus shells used to carry vaccines
4 February 2016 | By Victoria White
Researchers showed that virus-like particles carrying LXY-30 could home in on breast cancer cells both in a laboratory dish and in a mouse model...
List view / Grid view
Informatics
article
Drug Target Review’s top 10 stories from 2015
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
news
ADDoPT project set to transform the UK pharma industry
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
news
CRISPR used to repair genetic mutation in retinitis pigmentosa
27 January 2016 | By Victoria White
The study marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient's tissue...
news
Nanoparticles inhibit liver cancer tumour growth in study
26 January 2016 | By Victoria White
Scientists from UTSW have crafted synthetic "dendrimer" nanoparticles that are able to provide a tumour-suppressing effect without further damaging the liver or neighbouring tissue...
news
Neurodegenerative diseases: The potential of cyclophilin inhibition
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
news
LDC enters new drug discovery partnership with Roche
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
news
UC Berkeley researchers improve CRISPR-Cas9 gene editing technology
21 January 2016 | By Victoria White
The researchers have announced a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60% when replacing a short stretch of DNA with another...
news
PDi launched to enhance translation of phenotypic biology to novel therapeutics
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
news
Time to renew the antibiotic arsenal
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
news
Breast cancer study reveals new drug targets and combinations
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
news
Centauri acquires Alphamer technology from Altermune
18 January 2016 | By Victoria White
Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
news
Registration has now opened for Oxford Global’s 17th Annual Drug Discovery Leaders Summit
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
news
Boehringer and Arena to advance research in psychiatric diseases
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
news
Pfizer expands its R&D investment strategy
12 January 2016 | By Victoria White
The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy...
